Company intelligence / Profile preview

Ensemble Group Holdings

Ownership: Private
Development stage: Commercial

Overview

Ensemble Group Holdings has developed methods for treating cancer in patients with tumor proportion scores (TPS) for PD-1 or PD-L1 of 50% or less who are negative for lymphatic dysfunction, using immune checkpoint inhibition antagonists.

Therapeutic areas: Oncology
Modalities: Immune checkpoint inhibitors
Industry: Biotech

Drug pipeline

2 assets

lenvatinib

Commercial

Indications: Thyroid cancer, Renal cell carcinoma, Endometrial cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Ensemble Group Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ensemble Group Holdings.

Explore the full profile